Overview
CJC-1295 (With DAC) is a long-acting analog of growth hormone-releasing hormone. Its defining feature is the Drug Affinity Complex — a reactive maleimide group designed to bind circulating albumin, which slows clearance and produces a substantially extended activity window compared with non-DAC GHRH analogs. It is a reference tool for studying sustained endocrine signaling, long-acting peptide design, and downstream IGF-1 pathway activity.
Mechanism of Action
Like other GHRH analogs, CJC-1295 (With DAC) engages the GHRH receptor on pituitary somatotroph preparations, activating Gs-coupled adenylyl cyclase and cAMP-dependent growth hormone release. After exposure to biological media, the DAC moiety forms a covalent bond with albumin, shielding the peptide from enzymatic degradation and renal clearance — the basis for its prolonged receptor occupancy in experimental systems. Downstream research examines the resulting GH output, IGF-1 signaling, and the duration of endocrine response.
Specifications
- Purity: ≥99% (HPLC) with mass-spectrometry identity confirmation
- Form: Lyophilized powder
- CAS Number: 446262-90-4
- Molecular Weight: ~3647.2 g/mol
- Chemical Formula: C₁₆₅H₂₆₉N₄₇O₄₆
- Synonyms: CJC-1295 DAC
Research Applications
- GHRH receptor biology and long-acting analog pharmacology
- Pulsatile and sustained GH signaling comparison studies
- GH/IGF-1 axis pathway research
- Albumin-binding delivery-system models
- Peptide pharmacokinetics research





